entertainment -WSS

entertainment

author：fashion 2025-09-06 04:38:06 - browse：25

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

explore

focus

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Think you might have Covid

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Moderna hits safety problems in bold bid to reinvent medicine

Dewpoint Therapeutics lays off staff after losing partnerships

focus

entertainment

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In medicine, common shorthands can shortchange care

In Memoriam: Notable people who died in 2023

Readout Newsletter: Merck, J&J, and long Covid

Virginia high school admissions case could be legal follow

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Wildfire smoke exposes gaps in outdoor worker protections

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Moonlake's readout produced a cash windfall. Risks remain

Test for long Covid? Researchers find new clue in blood samples

entertainment

How digital therapeutics firms are pivoting after Pear's bankruptcy

NYC plans to house migrants on an island in the East River

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

The surgeon had a dilemma only a Nazi medical text could resolve

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Readout Newsletter: Merck, J&J, and long Covid

explore

focus

explore

knowledge